Last reviewed · How we verify
NCT05338411
Effect of Exogenous Growth Hormone on Ocular Findings
trial in Precocious Puberty in 90 participants. Status unknown.
22 October 2023
Quick facts
| Lead sponsor | Isfahan University of Medical Sciences |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 90 |
| Start date | 20 March 2022 |
| Primary completion | 22 October 2023 |
| Estimated completion | 22 October 2023 |
| Sites | 2 locations across Iran |
Conditions studied
- Precocious Puberty — all drugs for Precocious Puberty →
- Early Puberty — all drugs for Early Puberty →
- Refraction Error — all drugs for Refraction Error →
Sponsor
Isfahan University of Medical Sciences
Who can join
Adults 4 to 11, any sex, with Precocious Puberty or Early Puberty. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Body size and eye function play an essential role in adapting to the environment and human survival. Growth hormone is commonly recognized by its effect on the height of individuals; Although from an evolutionary perspective, the effects of growth hormone on eye development are more important. Although the effect of growth hormone on eye development has not been accurately determined, the results of a number of studies suggest the effect of growth hormone on eye development. Despite the large number of studies that have investigated the effects of growth hormone on height growth, there are few studies that have investigated the effects of growth hormone on the eye. To the best of our knowledge, no study has been conducted to investigate the effect of growth hormone on ocular findings of patients with early or precocious puberty. Therefore, we intend to investigate the effect of growth hormone on ocular findings of patients with early or precocious puberty.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05338411
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Precocious Puberty
Currently open trials in the same condition.
- NCT06510764 — A Trial of Chinese Traditional Medicine Combining With Intradermal Acupuncture for Treating Precocious Puberty · Phase 3 · recruiting
- NCT06280807 — Observation of Environment and Reproductive-Endocrine Effects · recruiting
- NCT04113070 — Overweight and Obesity and Puberty Development Cohort Study · recruiting
Other Isfahan University of Medical Sciences trials
Trials by the same sponsor.
- NCT06991933 — Construction and Educational Impact of Plastination Models of the Limbic System, Basal Nuclei, Cerebellum, and Human Spi · NA · not yet recruiting
- NCT07031960 — 3D Eye Movement Simulator for Medical Education · NA · not yet recruiting
- NCT07195370 — Testing YAG Laser Iridotomy for Primary Angle-Closure Glaucoma · NA · active not recruiting
- NCT06642363 — The Effectiveness of Astaxanthin Supplementation on the Clinical Symptoms and Cardio-metabolic Profile in Women with Pol · Phase 1 · recruiting
- NCT06379659 — Effectiveness of Intrauterine Growth Hormone Administration as an add-on Therapy to Conventional Hormone Therapy Compare · Phase 1, PHASE2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05338411 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Isfahan University of Medical Sciences
- Last refreshed: 21 April 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05338411.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing